Thermo Fisher の新しい免疫ペプチドミクス キットがカスタムペプチドワークフローに何を意味するか

Thermo Fisher の新しい免疫ペプチドミクス キットがカスタムペプチドワークフローに何を意味するか

Thermo Fisher の新しい免疫ペプチドミクス キットがカスタムペプチドワークフローに何を意味するか

Thermo Fisher Immunopeptidomics Kit and Custom Peptide Workflows

The landscape of antigen presentation research and neoantigen discovery is undergoing a major technological shift. The commercialization of standardized sample preparation and targeted quantitation kits—most notably Thermo Fisher Scientific’s SureQuant IP-MS sample preparation kits and Pierce MHC Class I Isolation systems—has brought unprecedented reproducibility to mass spectrometry-based immunopeptidomics.

歴史的に, immunopeptidomics relied on untargeted Data-Dependent Acquisition (DDA) to discover MHC/HLA-presented peptides from complex cell lysates. While effective for initial target discovery, untargeted DDA workflows suffered from high run-to-run variability, low sensitivity for low-abundance antigens, and poor inter-laboratory comparability.

With standardized kits, the industry is rapidly transitioning toward targeted quantitation—specifically Internal Standard Parallel Reaction Monitoring (IS-PRM) and SureQuant targeted workflows. This methodological evolution directly reshapes the requirements placed on upstream custom synthetic peptides. Synthetic reference peptides and stable isotope-labeled (シル) internal standards are no longer merely optional qualitative controls; they are integral quantitative reagents that govern assay sensitivity, dynamic range, and mass spectrometric accuracy.


The Shift from Discovery to Targeted Quantitation in Immunopeptidomics

Standardized kits streamline immunoaffinity enrichment by utilizing pre-validated antibody-coupled magnetic beads, optimized lysis buffers, and automated microfluidic digestion protocols. しかし, the true analytical power of these kits is unlocked when paired with targeted mass spectrometry on high-resolution Orbitrap mass spectrometers.

Immunoaffinity Capture <– Pre-validated MHC-I/II Antibody-Coupled Beads SIL Spike-In Standard <– Custom Synthetic Heavy Peptides (AAA Quantified)

Standardized Immunopeptidomics Workflow Cell Lysate / Tissue v v Acid Elution & Cleanup <– Separation of HLA Heavy Chains & Peptides v v Targeted nanoLC-MS/MS <– SureQuant IS-PRM / High-Resolution Orbitrap

In targeted IS-PRM assays, synthetic heavy isotope-labeled peptides matching suspected neoantigens or tumor-associated antigens (TAAs) are spiked into the sample prior to LC-MS analysis. The mass spectrometer monitors specific fragment ion transitions for both the endogenous “light” peptide (m/z light) and the synthetic “heavy” internal standard (m/z heavy).

As demonstrated in recent literature, such as a PubMed study on targeted HLA peptide quantification by IS-PRM, this targeted approach achieves attomole-level sensitivity, enabling the confident validation of low-copy-number MHC ligands that would otherwise be missed in untargeted screening.

重要なポイント: The adoption of standardized immunopeptidomics sample prep kits moves the field from qualitative identification to rigorous quantitative verification. その結果, synthetic reference peptides must meet stringent chemical, isotopic, and physical specifications to avoid compromising targeted LC-MS assays.


Upstream Peptide Specifications: What Standardized Kits Demand

When researchers integrate targeted immunopeptidomics kits into their pipeline, upstream custom peptide specifications must be recalibrated. Standard academic-grade synthetic peptides (例えば, 70–80% crude purity with residual counterions) introduce significant analytical artifacts into nanoLC-MS/MS systems.

  • Ion-Pairing Effect: TFA causes severe ESI signal suppression in nanoLC-MS
  • Gravimetric Defect: 水分 + counterions introduce 10-30% weight error
  • 解決: 6M HCl microwave hydrolysis + LC-MS AAA for net peptide content

Critical Custom Peptide Quality Pillars GLP 1 Tripeptide Company

  1. 化学薬品 & Isotopic Purity
  • RP-HPLC 純度: >95% に >98%
  • 同位体濃縮: ≥99 atom % 13C and 15N (C-terminal Lys/Arg)
  1. トリフルオロ酢酸 (TFA) Counterion Removal
  • Specification: Salt exchange to Acetate/HCl ペプチドの (残留TFA < 1.0%)
  1. Absolute Quantitation via Amino Acid Analysis (AAA)

Isotopic Enrichment and Isotopic Purity Thresholds

For targeted IS-PRM and SureQuant assays, stable isotope-labeled (シル) internal standards are synthesized by incorporating heavy amino acids at the C-terminus, 通常 [^{13}C₆, ^{15}N₂]リジン (Δm = +8.0142 そして) または [^{13}C₆, ^{15}N₄]アルギニン (Δm = +10.0083 そして).

To guarantee absolute quantification accuracy:

  • Isotopic Purity: The heavy amino acid precursors must possess ≥ 99 atom % a ^{13}C and ^{15}N enrichment.
  • Unlabeled Contamination Rate: Unlabeled “light” peptide contamination within the heavy standard must be < 0.1%. High levels of light impurity artificially inflate endogenous peptide measurements.
  • Mass Shift Integrity: の +8 Da or +10 Da mass shift ensures that isotopic envelope tailing from the heavy standard does not overlap with the monoisotopic m/z window of the endogenous analyte.

Counterion Removal: Mitigating TFA Ion Suppression

During Solid-Phase Peptide Synthesis (SPSS), cleavage from resin and subsequent Reverse-Phase HPLC (RP-HPLC) purification rely heavily on trifluoroacetic aci

Electrospray Ionization (ESI) Suppression: CF_3COO^- ions form strong gas-phase ion pairs with positively charged basic H36 Peptide Wholesale 残留物 (Lys^+, Arg^+, and N-terminal NH_3^+), neutralizing peptide charges and dramatically reducing ionization efficiency.

ong>: CF_3COO^- ions form strong gas-phase ion pairs with positively charged basic residues (Lys^+, Arg^+, and N-terminal NH_3^+), neutralizing peptide charges and dramatically reducing ionization efficiency.

  • Chromatographic Retention Drift: Residual TFA acts as a strong hydrophobic ion-pairing reagent, altering nanoflow liquid chromatography retention times and causing peak tailing.

⚠️警告: Using synthetic reference peptides containing residual TFA in nanoLC-MS/MS can suppress the ionization of co-eluting low-abundance MHC peptides by up to 80%, leading to false negatives in neoantigen validation.

Standardized immunopeptidomics workflows mandate a counterion exchange process. By converting peptide salts from trifluoroacetate to acetate (CH_3COO^-) または塩酸塩 (Cl^-), residual TFA content is reduced to < 1.0%, ensuring stable nanoESI signal response.

Absolute Concentration Verification via Amino Acid Analysis (AAA)

In targeted SureQuant assays, the accuracy of endogenous peptide quantification is directly proportional to the accuracy of the spiked SIL internal standard concentration.

Relying on gravimetric mass measurement (weighing lyophilized peptide powder) is inherently inaccurate due to variable hydration (5–15 wt%) and residual counterion mass (10–25 wt%). A vial weighed as 1.0 mg of peptide powder may contain only 0.70 mg of net active peptide.

To achieve exact molar calibration:

  • Microwave Acid Hydrolysis: Peptides are hydrolyzed in 6 M HCl at 110°C or under microwave heating for 1–2 hours.
  • 液体クロマトグラフィー - 質量分析法 (LC-MS) AAA: Hydrolyzed free amino acids are quantified against NIST-traceable reference standards, as outlined in a Journal of Proteome Research analysis on amino acid analysis for absolute peptide quantitation.
  • 正味ペプチド含有量 (NPC): The exact molarity and NPC percentage are recorded on the Certificate of Analysis (CoA), enabling precise picomole-level spike-in preparations.

Turnaround Dynamics and High-Throughput Format Requirements

The clinical translation of immunopeptidomics—such as personalized cancer vaccine development and cell therapy antigen validation—imposes tight operational timelines. Researchers using automated sample preparation platforms cannot afford multi-month turnaround times for custom peptides.

High-Throughput Immunopeptidomics Delivery Matrix Neoantigen Target Prediction → In Silico HLA Binding Algorithms Rapid Custom Synthesis → 10 – 14 Business Days Turnaround Parallel Processing → 96-Well Micro-Aliquoted Format Vessel Surface Optimization → Low-Binding Polypropylene / Pre-Dissolved Targeted LC-MS/MS Assay → Attomole Validation via SureQuant IS-PRM

Key operational adaptations described in a PMC protocol on immunopeptidomics sample preparation 含む:

  • 10–14 Day Fast-Turnaround Synthesis: Automated parallel SPPS platforms capable of synthesizing 96 に 384 distinct peptides simultaneously.
  • 96-Well Pre

    Non-Specific Adsorption Mitigation: HLA-bound peptides are predominantly hydrophobic 8–11-mers (Class I) or 12–25-mers (Class II) that readily stick to standard plastic surfaces. Micro-aliquoting into low-binding polypropylene vessels or supplying peptides in pre-dissolved DMSO/ACN matrices prevents hydrophobic sample loss. ペプチド合成

    d plastic surfaces. Micro-aliquoting into low-binding polypropylene vessels or supplying peptides in pre-dissolved DMSO/ACN matrices prevents hydrophobic sample loss.


Practical Adaptations for Custom Peptide Providers

To help researchers adopt standardized immunopeptidomics kits with confidence, peptide synthesis providers must evolve from passive order-fulfillment shops into specialized solution partners.

Strategic Adaptations for Custom Peptide Providers Adaptation 1: 厳選された免疫ペプチドミクス対応カタログ & Anchor Libraries

  • Pre-synthesized reference panels for common alleles (HLA-A02:01, あ24:02) Adaptation 2: Targeted QC Panels & Multi-Metric Certificates of Analysis
  • ESI-HRMS mass accuracy (< 2 ppm), RP-HPLC traces, 残留TFA %, and AAA Adaptation 3: Rapid Labeling & Specialized Modification Services
  • ペプチド合成 Stable isotope incorporation, N/C-terminal tags, とクラス 100 sterile QC

厳選された免疫ペプチドミクス対応カタログ & Allele-Specific Panels

Peptide providers should offer curated, off-the-shelf reference panels based on well-characterized HLA allele anchor motifs.

  • Class I Panels: Covering high-frequency alleles such as HLA-A02:01, HLA-A24:02, HLA-B07:02, and HLA-C07:02. These panels contain validated nonamer ($9$-メール) and decamer ($10$-メール) peptides with canonical anchor residues (例えば, Leu/Met at Position 2 and Val/L-Leu at Position 9 for HLA-A*02:01).
  • Class II Panels: Covering HLA-DRB101:01, HLA-DRB104:01, and HLA-DQ8, incorporating longer 13–17-mer sequences with verified solubility characteristics.

Having off-the-shelf panels available for immediate dispatch acc

Providers should supply comprehensive CoAs containing: Peptide Therapeutic Supplier

and retention time alignment (例えば, iRT calibration) for LC-MS runs.

Targeted QC Panels and Comprehensive Certificates of Analysis

A robust Quality Control (品質管理) panel for immunopeptidomics reference peptides must extend beyond basic MALDI-TOF mass spectra.

Providers should supply comprehensive CoAs containing:

  1. High-Resolution ESI-HRMS Spectra: Verifying monoisotopic mass and charge states ([M+H]^+, [中+2時間]^{2+}, [中+3時間]^{3+}) with mass error < 2 ppm.
  2. RP-HPLC Chromatograms: Demonstrating >95% または >98% chemical purity with explicit gradient conditions.
  3. Residual TFA Determination: イオンクロマトグラフィー (IC) or 19F-NMR quantification showing residual TFA < 1.0%.
  4. Net Peptide Content via AAA: Precise nanomoles/vial values to guarantee reproducible internal standard spike-ins.

チップ用: When requesting custom SIL peptides for targeted immunopeptidomics, always ensure the vendor provides AAA-certified net peptide content and TFA-free salt exchange. This single step eliminates the primary source of inter-batch quantification bias in Orbitrap LC-MS assays.

Rapid Heavy-Isotope Labeling and Micro-Aliquoting Services

Providers must streamline the synthesis of complex modified peptides, 含む:

  • Automated Heavy Isotope Incorporation: High-efficiency coupling of [^{13}C₆, ^{15}N₂]Lys and [^{13}C₆, ^{15}N₄]Arg without isotopic dilution during cleavage.
  • Terminal & Internal Modifications: Biotinylation, 蛍光団結合 (例えば, FITC, Cy5), N-terminal acetylation, and click-chemistry handles (azide/alkyne) for multi-modal antigen tracking.
  • Sterile Cleanroom Processing: For downstream functional bioassays (例えば, T-cell activation assays, ELISpot, or TCR binding assays), peptides must be processed under sterile cleanroom conditions with endotoxin testing (< 0.01 EU/μg).

Strategic Partnership: Elevating Immunopeptidomics Workflows

Navigating the complexities of targeted immunopeptidomics requires close alignment between reagent kit manufacturers, mass spectrometry core facilities, and specialized peptide synthesis partners.

As a dedicated leader in peptide manufacturing, の MOL、カスタムペプチド合成プラットフォームを変更 provides an integrated infrastructure specifically engineered to support advanced immunopeptidomics and neoantigen discovery programs.

MOL Changes Immunopeptidomics Engine

High-Throughput SPPS Salt Exchange Platform AAA Quantitation Suite Class 100 クリーンルーム

→ Synthesis of Complex & Hydrophobic Peptides → TFA Counterion Removal (< 1.0% 残留TFA) → Certified Net Peptide Content & Exact Molarity → Endotoxin-Free & Sterile Lyophilization

活用することで high-purity peptide modifications and TFA removal services, researchers can seamlessly bridge the gap between kit-based sample preparation and high-confidence targeted LC-MS quantification. さらに, 内での生産 無菌クラス 100 クリーンルーム製造 facilities ensures that synthetic peptide standards are immediately suitable for both analytical mass spectrometry and cell-based immunological validation.

Standardized sample prep kits have revolutionized immunopeptidomics sample processing. By pairing these kits with custom synthetic peptides engineered for strict isotopic purity, TFAの除去, and certified AAA quantitation, researchers can establish robust, high-throughput pipelines that drive neoantigen discovery and immunotherapy forward with complete confidence.

管理者のアバター

ゼジュン・ペン

最高技術責任者; ペプチド合成のエキスパート コアの専門知識: 複雑なペプチド合成, 非天然アミノ酸修飾, 環状ペプチドとステープルペプチドの構築.

バイオグラフィー:Zejun Peng は有機化学とペプチド合成において豊富な経験を持っています. 彼は固相ペプチド合成の組み合わせ応用に熟達しています。 (SPSS) および液相ペプチド合成 (LPPS), 特に「合成が非常に難しいシーケンス」を克服することに長けています。 (超長鎖ペプチドなど, 疎水性の高い配列, および複数のジスルフィド結合の折り畳み). 彼のリーダーシップの下で, チームはいくつかの特殊な変更で技術的なボトルネックを克服することに成功しました。 (N-メチル化など, PEG化, そして蛍光標識), 以上の合成成功率を維持する 98%.

事実確認済み & 編集ガイドライン
レビュー者: 対象分野の専門家
この記事をシェアする
検索 ワッツアップ サービス 製品